H.C. Wainwright lowered the firm’s price target on Gossamer Bio (GOSS) to $5 from $10 and keeps a Buy rating on the shares. The firm reduced its probability of success for seralutinib in pulmonary arterial hypertension to 50% from 70%.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GOSS:
- Gossamer Bio price target lowered to $3 from $12 at Oppenheimer
- Vanguard Total Stock Market ETF (VTI) Daily Snapshot—2/25/26
- Gossamer Bio downgraded to Neutral from Buy at Goldman Sachs
- Is the SPDR S&P Biotech ETF (XBI) a ‘Strong Buy’ Right Now?
- Midday Fly By: Home Depot reports Q4 beat, AMD and Meta expand partnership